Questions discussed in this category

There are various formulations of intravenous iron; each with varying costs, test dose requirement, elemental dose, and number or time of infusions ne...

If there are a low-risk patients who can be monitored, how would you do so? If unprovoked, would you consider stopping anticoagulation?

Individuals with MPNs may be at higher risk for thrombosis and be placed on antiplatelet therapy or even anticoagulation because of prior thrombosis. ...

Should we use a different dose in critically ill patients in the ICU? When should we consider intermediate-dose anticoagulation?

Aside from addressing the underlying case, is there a role for phlebotomy in secondary polycythemia such as in COPD or post-renal transplant erythrocy...

Is there a preferred strategy of transfusional support versus reduced-dose anticoagulation during the duration of thrombocytopenia?

In this scenario, is systemic treatment better given bilateral involvement? In a patient who has already had cataract surgery and is not at risk for c...

 Does your dose recommendation change if a patient has cord compression or has undergone surgery? There is a range of doses in the ILROG guidelin...

Hydroxyurea is demonstrated to reduce complications and improve long-term outcomes in severe genotypes HbSS and sickle beta0 thalassemia. What clinica...

Are there major differences in standard conditioning and/or GVHD prophylaxis regimens utilized? Does the non-relapse mortality different significantl...

Is there any data justifying the use of systemic therapy over localized therapy (e.g. radiation or surgery) in this situation prior to a progression e...

While L-glutamine has minimal side effects and would likely be added after hydrea, how do you decide between the use of voxelotor and crizanlizumab?

During the Stimate recall, how are we performing DDAVP challenges for newly diagnosed hemophilia A or von Willebrand disease?

Rituximab has entered the treatment algorithm in the first-line setting for the initial treatment of TTP. However, in remission, the role of adjuvant ...

What are your target goals during transfusion, either prophylactically or during acute complication? Does your management change between vaginal deliv...

How does age play a role in this decision?  If you do intensify therapy, how do you explain the negative results of CALGB/Alliance 50303?

Does your opinion change based on the specific underlying inherited thrombophilia? The original case was a central retinal artery occlusion in a patie...

Especially in a patient without hemophilia or thrombosis history?

Do you only give intrathecal chemotherapy or systemic therapy?

What are the scenarios in which a rebiopsy is warranted for follicular lymphoma?

Can results from emerging AML data be extrapolated to high risk MDS populations? Is there data to guide the choice of continuing the HMA in combinati...

Would you offer this routinely or only if specific complications arise, such as distal emboli?

Does the absence of an OS benefit in the AG221-AML-005 presented at ASCO 2020 deter you from this strategy?

At what point would you recommend transfusion? At what point would you stop radiation?

In patients who are intolerant to hydroxyurea, anagrelide and interferon

Is there any benefit to getting it prior to starting cytoreduction?

Would it make a difference if the VTE diagnosis occurs during bevacizumab therapy or whether it preceded the cancer diagnosis?

Is it at neutrophil recovery, at documentation of CR on bone marrow biopsy, or is there a different point in time?

The patient received R-EPOCH followed by consolidative RT (36 Gy in 18 fractions) approximately one year ago and was subsequently salvaged with RICE.

Assuming CBC w/ different and complete metabolic panel are within normal limits, what (if any) further evaluation or management is needed?

TROG 99.03 showed nearly 20% improved PFS at 10 years with chemoimmunotherapy despite 31/75 patients assigned R-CVP vs 44/75 assigned CVP without ritu...

For example, for joing replacement surgery? Do you hold the revlimid for certain about of time before and after?

Is there a preference for obinutuzumab over rituximab in early relapsed DLBCL, or in primary refractory disease?

There seems to be a wide variety of palliative doses used in clinical practice (8 Gy x 1, 2 Gy x2, and 20 Gy in 10 fx).  Do you have a preferred ...

For instance, would you discontinue when there is resolution of adenopathy and normalization of counts? If so, do you overlap ibrutinib with other the...

At what age would you treat an early stage hodgkins lymphoma patient with ABVD + RT (adult treatment) vs OEPA x 2 or AV-PC x 3 (pediatric paradigm)?&n...

The unfavorable risk factors for stage I-II Classic Hodgkin's Lymphoma differ depending on the cooperative group (GHSG, EORTC, NCCN), which criteria d...

Given the rarity of DLBCL with MYC/BCL2/BCL6 rearrangements, do you approach this disease differently than DLBCL with MYC/BCL2 or BCL6 rearrangement, ...

Guidelines indicate RCHOPx3 +RT as category I and RCHOP x 6 below that; long term f/u for SWOG 8736 showed similar PFS and OS. Do you have and approac...

Do the potential late effects offset any benefit of mediastinal XRT in a young patient with bulky disease?

To me, the recent NEJM study is flawed in that the control arm did not have maintenance treatment while the experimental arm used maintenance Dar...

Would you proceed to autologous transplant, or switch to an alternate regimen (eg. daratumumab-based) first? Would the type or degree of organ involv...

In a patient with no evidence of bleeding, do you use a platelet cutoff? Do you utilize genomic testing (eg CALR, MPL, JAK2, etc.) to decide on cytore...

Once a tissue biopsy has confirmed light chain amyloid, what additional tests do you perform as part of a standard workup? In whom should treatment b...

Do these events mandate discontinuation of lenalidomide therapy or switching to a different agent? Can appropriate therapy for these skin cancers be r...

For a stage IAE DLBCL (in this case, of the oral cavity) that was completely excised, s/p R-CHOP, is the ISRT target volume just the preop volume plus...

Specifically, do you consider repeating maintenance therapy after second line therapy if a patient had already received 2 years of maintenance rituxim...

If a young and otherwise healthy patient with normal echocardiogram and no other cardiac risk factors needs treatment for DLBCL, but has previously re...

Would you still proceed to high-dose therapy and autologous SCT? Would you incorporate radiation pre- or post- transplant? Or offer additional salvag...

Specifically, do you utilize 3 cycles of chemo with ISRT or 6 cycles? Do you use R-EPOCH or R-CHOP in these cases?

For instance, do you ever start with dasatinib 50 mg daily?  Are there any titration schedules that you follow?

Given the PFS benefit seen in the most recent ECOG-ACRIN, and the prior study of Rd showing an OS benefit, is your practice to put any high-risk SMM p...

e.g. mixed indolent/aggressive NHL, mixed NHL/HL? Is there a definitive way to discern composite from transformation? NCCN does not list recommendatio...

if so, are there specific cytogenetic, molecular, clinical, or hematologic factors that you take into consideration?

The patient is not a transplant candidate due to multiple co-morbidities. Some of the sites in question have had a complete response and other have ha...

How would you handle high risk features (eg double hit) with the limitations of dialysis?

Would you give 3 cycles of RCHOP followed by consolidative IFRT or 6 cycles of R-mini CHOP? Is there a role for 3 cycles of R-mini CHOP followed by IF...

Thrombosis was ruled out and no etiology was found.  Would you start ponatinib back at a lower dose, transition to omacetaxine or begin transplan...

Would your recommendations change if the mass were significantly smaller, say 1-2 cm, and was completely excised with negative margins?  

Given nationwide shortage in Vinblastine, several of my patients under active therapy are facing delays in their therapies. Is it appropriate to subst...

Some specific questions: Would you recommend repeat biopsy to confirm residual disease? How would your recommendations vary if the patient had pre...

Do you await molecular and cytogenetic results prior to initiating therapy, or does age and function status primarily drive your choice?

NCCN does not list any preferences for the TKIs in their guidelines.

If the breast was previously radiated 15 years ago, would that change your decision?  If there was residual lymphoma on cytology of a chronic se...

I.e., Can day 2 Rituximab (RCHOP) or day 6 Rituximab (DA-EPOCH, Hyper CVAD) be given? Or should only Day 1 Rituximab be used with chemoimmunotherapy i...

Would you recommend RCHOP x 3-6 or RCHOP x 3 + ISRT?  If you end up doing ISRT, would your target be any different than the principles that guide...

Since some prior studies (eg. Eskelund et al. Blood 2017 130:1903-10.) have shown intensive chemoimmunotherapy does not overcome the ad...

Since ECHELON-1 trial showed an improvement in PFS (but not OS), are there any situations where you would replace bleomycin with brentuximab...

Is your scoring based on SUV uptake vs the subjective interpretation of the radiologist? How do you go about reconciling Deauville scoring when there ...

For example - Would you offer tandem transplantation in a young, fit patient in a CR after first transplant, but with MRD detectable?

Would you follow an algorithm such as the one proposed by Hall et al? How do you decide between intrathecal chemotherapy vs systemic therapy with HD-...

FDA package insert lists posaconazole as strong cyp3A4 inhibitor and states to consider other therapies.

Does presenting total white blood cell count affect your decision? Does myeloid subtype affect your decision? 

How might your decision change if the patient had a suitable 10/10 donor? How about if the patient had a targetable molecular mutation such as IDH2?

Repeat EGD and additional biopsies of the stomach were all negative for MALT lymphoma and H. Pylori. A CT of the C/A/P was done showing no evidence of...

Although the MMR vaccine is contraindicated in immunosuppressed patients on anticancer treatment according to CDC/ACIP and IDSA guidelines, data on sa...

For example, would you go ahead with 20 Gy of ISRT if medical oncology has already treated a stage I-IIA patient with 2 cycles of ABVD meeting all oth...

If they are symptomatic do you relax that time interval? Do you ever consider partial brain radiation instead of whole brain to minimize neurotoxicity...

In a patient who absolutely cannot receive chemotherapy due to impaired performance status, what dose would you use for WBRT and what dose would you u...

Prior trials of systemic therapy including alkylating agents and rituximab have failed and the patient is medically inoperable with no history of Hepa...

The staging bone marrow biopsy was negative. The staging manual simply states "bone involvement is identified using appropriate imaging studies."...

Given the recent results presented from the Griffin trial, would you choose a daratumumab-based regimen (eg. D-VRd) over other salvage options (V...

Would you use a similar dose and fractionation as gastric MALT (30Gy in 1.5 Gy fractions)?

We know the longer we expose patients to lenalidomide, the harder collection will be. Would you collect now or switch to an alternative regimen to ach...

Would the site of disease relapse play a role in your decision (i.e. isolated lymph node recurrence versus failure at primary site of disease)?

Has the recent data presented at ASH affected your choice of regimen? Would your choice differ between transplant-eligible and transplant-ineligible ...

Shanafelt et al. recently presented results from the phase III E1912 study at ASH 2018. Will you still utilize FCR as first-line or now use Ritux...

Would MRD assessments affect your clinical decision making for MM patients outside of a clinical trial?

Do you generally always boost the scalp and/or soles even if those sites are not involved with disease?  

Would you consider observation following surgical resection with negative margins? Would you recommend WBRT and/or ISRT? What would be your preferred ...

Specifically, what regimen would you choose in a patient with new renal failure but not requiring dialysis?

What factors influence your decision (patient/disease characteristics, additional agents added to induction chemotherapy, CR1 or later, etc)?

If a patient obtains a PR or less to front line cladribine, what factors help you chose between a second course of cladribine, an alternative pur...

When is it warranted to utilize targeted therapies for known mutations (eg. midostaurin or an alternative TKI for FLT3 mutations, ivosidenib for ...

Does the choice of initial induction regimen affect your decision for when to employ lenalidomide maintenance? Are there situations where you would c...

Are you routinely using letermovir as CMV prophylaxis in high-risk patients? Any special considerations with its use versus other antiviral agents? ...

Would you treat differently for de novo disease vs disease arising from large cell transformation of an indolent NHL?

Given the rarity of this in MF, is it still predictive of response to lenalidomide therapy?

Does their candidacy for autologous HSCT affect your decision to use maintenance lenalidomide?

The patient had a bilateral orchiectomy (pathology demonstrated no invasion of the tunica) followed by R-CHOP x 6 and IT Mtx with a PET CR in a para-a...

The patient is a 75 yo immunocompetent man who has a history of inverted papilloma of the sinuses and presented with a new lesion in the right maxilla...

Does the more recent data regarding the continued utility of brentuximab vedotin and the utility of PD-1 inhibitors factor in to your reasoning at all...

Could one make a case for addition of Rituxinab frontline to increase the chances of a complete remission and even maybe achieve MRD-negative status ?

Does it differ from the treatment of other relapsed peripheral T-cell lymphomas? Are there any clinical trials or case series focused on SPTCL? Is t...

Given the rarity of this diagnosis (5-7% of all AL amyloidosis cases), and the prognostic and clinical differences when compared to non IgM-AL am...

Technically, you can have up to 55% of larger cells circulating and still be called CLL.

Would you use 10 Gy in 1 Gy per fraction as mentioned in a litterature review in Pubmed?

Once you decide to begin treatment, any special precautions you would use for protein levels starting that high.

The patient does have significant weight loss, drenching night sweats, but no evidence of other involved sites on PET, thorough skin exam, and has nor...

In the case of an excised groin node with no residual disease and no chemotherapy in a young adult patient, how large should the fields be? Is it requ...

Assuming that the involved area is too widespread for RT. Would you try single agent rituximab first? Or obinutuzumab? What if rituximab alone gave on...

The recent NEJM phase II trial http://www.nejm.org/doi/full/10.1056/NEJMoa1715519?query=featured_home looked at a small cohort of 24 patients and show...

the MZL was untreated in the past prior to transformation. Do these patients have a higher risk of recurrence post CR as opposed to patients with de ...

I have a patient with low volume disease of Castleman's disease with cervical lymphadenopathy and tonsillar hyperplasia that is suspicious but not bio...

If a patient has an increase in PET avidity between the PET/CT done after 2 cycles of ABVD and after completion of chemo, how would you proceed? Would...

Specifically, in patients that had progression or developed toxicity on ibrutinib? Idelalisib is very toxic and venetoclax a labor-intensive drug to g...

Even though Venetoclax is not FDA-approved yet, assuming you can get it off label? 1. Gemtuzumab: What dose/schedule and which HMA? 2. Venetoclax: W...

My practice had always been to transfuse for plts < 10, but the recent ASCO guideline change suggests  that in the post-autoSCT setting it is ...

Does your follow-up differ depending on the dose you used (e.g. boom boom vs. 24 Gy)?  Do you routinely image?  If so, do you use MRI or PET...

If filgrastim, how many days would you give? Pegfilgrastim is often not covered by payers if given less than 14 days before chemotherapy.  

The patient has no medical problems and no history of leukemia/MDS. Biopsy of the filum terminale and arachnoid confirmed a myeloid sarcoma and MRI sh...

Subq has been shown to have lower risk of neuropathy. Is there any reason to use weekly IV still?

This is a recently described entity with poor prognosis, so even with a CR after RCHOPx6 cycles, is your bias to push for ISRT due to EBV being poor p...

In a patient with multiple poor risk features including TP53 mutation, 1q amplification, stage III, and circulating plasma cells, would you consider a...

For example, how significant does the M protein have to increase for you to begin a conversation about new therapy?

If the patient had a CR by PET/CT after 2 cycles of ABVD and received 6 cycles of ABVD would you recommended consolidating only the bulky disease and ...

Specifically, to you lean towards elotuzumab or a daratumumab-based regimen?

What technique do you use (IMRT vs direct electrons w bolus)?  The ILROG paper on extranodal NHL says "For tumors confined to the conjunctiva or...

Peripheral blood Flow shows prominent NK cell population but marrow aspiration/bx shows normocellular marrow with trilineage hematopoeisis.  &nb...

If a patient will receive a total of 4 cycles ABVD and has a CR by PET/CT after cycle 2, can RT be omitted to non-bulky sites to avoid toxicity?

Would you change your radiation therapy treatment dose or volume if you needed to treat a chloroma? If a patient had a separate cancer (e.g. skin canc...

If the patient cannot tolerate methotrexate or further chemotherapy, how effective is radiation therapy (e.g. WBRT) in rendering the patient disease-f...

Specifically I am thinking if a PET scan shows complete response, would it be reasonable to stop bleomycin and continue AVD?

My experience has been that patients can be neurologically devastated years out from WBRT. In Medical Oncology practice at my institution, we do not r...

Drug information indicates a patient may need 3-4 months off TKI. This seems like a long time off drug. Would a MMR of a certain duration make it less...

Specifically when given as a single agent. Any role for G-CSF?

PET/CT/bone marrow biopsy negative for evidence of distant disease. Following 4 cycles of combination chemotherapy with no evidence of progressive dis...

For example: would you treat the entire Waldeyer's ring?  For a stage II patient who also has cervical lymph node involvement on one side, do you...

At what point is the neuropathy a contraindication to further bortezomib therapy?

Although bendamustine + rituximab is a standard option for advanced follicular lymphoma when treatment is required, does the regimen rituximab + lenal...

Specifically, can you rechallenge after the effusion has resolved (e.g. therapeutic thoracentesis)? If so, how long do you wait to rechallenge (especi...

Imatinib, or a second-generation TKI? Are there specific factors that make you choose one over the other?

We often see young women with favorable, early stage disease in the mediastinum who have had a complete response to chemotherapy. With current smaller...

If so, do you use antivirals and/or antibiotics? Does it matter if the patient has mantle cell lymphoma, CLL, or Waldenstrom's macroglobulinemia?

Specifically, do you just wait for count recovery? Do you check for morphologic or molecular remission at all during this time?

Do you re-challenge them?  If so, what pre-medications do you give?  Do you dose reduce the cytarabine? Or do you switch another regimen?

Specifically, is there still a role for dd RCHOP followed by ICE, or do you recommend DA-R-EPOCH for all patients?

Would you include one vertebral body above and below the involved vertebral body? Is IMRT appropriate in order to reduce dose to small bowel? What oth...

NCCN guidelines suggest XRT as standard of care for this stage of disease. However, occasionally patients have their tumors completely excised when un...

Would you continue ibrutinib even if they are placed on anti-platelet therapy such as clopidogrel or ticagrelor?

If a patient had recently completed R-EPOCH x 6 cycles, would you change your dose for a low grade follicular lymphoma?

If the mesentery is widely involved with small lesions would this change your management? What if the patient was symptomatic? 

What is the utility of repeating FISH studies to evaluate for clonal evolution if FISH studies were done at diagnosis?  

With the field moving more toward ISRT/ INRT, and conformal radiation, would you generate separate PTV for initial nodal involvements that are within ...

When nodal regions not amenable to biopsy but are enlarged without significant SUV uptake, should they be treated as involed and recieve RT?

After ABVE-PC X4 and Ifos/vinorelbine x 2 per AHOD 0831 (and is unable to have these sites biopsied), what dose would you treat to and what volume wou...

When radiation therapy is utilized, what should the radiation therapy treatment fields include and what imaging studies should be completed to assist ...

If so, should involved site radiation thearpy (ISRT) or involved field radiation therapy (IFRT) be used for the radiation therapy treatment fields? Wo...

When the disease (in this case, lymphoma) involves almost all of the entire muscle compartment of the distal lower extremity, what is a safe dose? I'm...

In drawing the lung blocks approximately 1 cm in from the chest wall, diaphragm and mediastinum, should the blocks stop underneath the clavicle o...

If a patient with stage I, low grade follicular lymphoma achieves a complete response after rituxan and treanda is there any role for consolidative ra...

Is it necessary to treat the whole orbit or is conformal treatment ok? 

After a nerve sparing parotidectomy, would you offer postoperative radiotherapy? If so, what volume and dose? Would it change your management if the p...

In a patient with Stage IE DLBCL, is your treatment volume postchemo ISRT or whole breast? Would you consolidate if a lumpectomy was performed prior t...

Would you prescribe to a higher dose? Treat with wider margins? Encourage the use of systemic therapy?

Hoskin et al (Lancet Oncology 2014) suggest 24Gy/12fx is more effect RT dose compared to 4Gy.

Is there a benefit to IMRT when we treat to relatively low doses (as compared to squamous cell cancers of the head and neck)?

Or is it more appropriate for certain sites/stages/histologies?

It seems that with the arms up, you get better lung blocking but with arms akimbo, you might have a lower dose to the humeral head. 

Papers discussed in this category

Int. J. Radiat. Oncol. Biol. Phys., 2011-07-15

International journal of radiation oncology, biology, physics, 2014-07-15

International journal of radiation oncology, biology, physics, 2014-05-01

Lancet Oncol., 2014-04-01

J. Clin. Oncol., 2014-04-10

J. Clin. Oncol., 2013-11-10

Oncology (Williston Park, N.Y.), 2012-12

N. Engl. J. Med., 2010-08-12

The New England journal of medicine, 2013-04-11

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-11-10

Practical radiation oncology, 2015

International journal of radiation oncology, biology, physics, 2015-05-01

J. Clin. Oncol., 2015-09-10

Cancer, 2004-08-15

Br. J. Haematol., 2003-11-01

Br. J. Haematol., 1998-08-01

Cancer, 1990-11-15

Radiother Oncol, 1990-01-01

International journal of radiation oncology, biology, physics, 2015-05-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-10-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-05-10

The New England journal of medicine, 1998-07-02

Annals of internal medicine, 1994-06-01

The New England journal of medicine, 2010-06-17

Blood, 2014-01-23

The New England journal of medicine, 2010-06-17

Journal of palliative medicine, 2015-07

The New England journal of medicine, 2015-12-17

Turk J Med Sci,

Radiat Oncol, 2015-03-28

Medical and pediatric oncology, 1981

JAMA, 2013-04-03

Haematologica, 2016-12-01

Clin Pharmacokinet, 2012-12-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-09-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-07-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-08-10

J Clin Oncol, 2010 Oct 10

J. Natl. Cancer Inst., 2011 Oct 21

The Lancet. Oncology, 2016-08

J. Clin. Oncol., 2010 May 03

Blood, 2016-10-13

Int. J. Radiat. Oncol. Biol. Phys., 2017-01-01

International journal of radiation oncology, biology, physics, 2008-08-01

International journal of radiation oncology, biology, physics, 2015-05-01

International journal of radiation oncology, biology, physics, 2015-05-01

Ann. Oncol., 1996-09-01

The Lancet. Oncology, 2014-11

International journal of radiation oncology, biology, physics, 2013-03-01

Int. J. Radiat. Oncol. Biol. Phys., 2009-05-01

Int. J. Radiat. Oncol. Biol. Phys., 1983-10-01

Clinical lymphoma, myeloma & leukemia, 2014-12

The New England journal of medicine, 2016-06-23

Blood, 2013-12-19

Cancer, 2004-05-15

Blood, 2016-12-22

N. Engl. J. Med., 2015-04-23

Leuk. Lymphoma, 2007-09-01

The New England journal of medicine, 2015-08-13

N. Engl. J. Med., 2018-01-25

British journal of haematology, 2004-04



Br. J. Haematol., 2017 Nov 21

American journal of hematology, 2016-05

Blood, 2018-06-21

Nature, 2019-06

Leukemia, 2019-02

The Lancet. Oncology, 2009-03

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-05-15

Cancer, 2011-06-15

American journal of hematology, 2009-09

Cancer, 2010-08-15

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-12-15

Lancet, 2009 Sep 18

Blood, 2013-11-14

J. Clin. Oncol., 2016 Jan 25

Leukemia, 2016-02

The Lancet. Oncology, 2018-02

The Lancet. Oncology, 2010-01

The New England journal of medicine, 2014-09-04

The New England journal of medicine, 2019-05-30

Lancet (London, England), 2017-02-04

The New England journal of medicine, 2018-02-08

Journal of the American Academy of Dermatology, 2016-11

Leukemia & lymphoma, 2014-04

Cancer, 1994-01-01

Med. Pediatr. Oncol.,

Arch. Dis. Child.,

Pediatric blood & cancer, 2018-05

Br. J. Haematol.,

The New England journal of medicine, 2017-12-28

Leuk. Lymphoma,


JAMA oncology, 2018-02-01



Blood, 1998-09-01

American journal of hematology, 2017-01

Avicenna J Med, 2017 Jul-Sep

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-10-10

The New England journal of medicine, 2016-11-24

The Lancet. Haematology, 2018-01

Blood, 2014-05-22

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-09-10

J. Clin. Oncol.,


Lancet (London, England), 2018-02-17

British journal of haematology, 2017-11

Fertil. Steril., 2013 Sep 05

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-05-10

Int. J. Radiat. Oncol. Biol. Phys., 2012 Jun 05

Leukemia, 2018-08

The New England journal of medicine, 2015-10-29

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-04-10

Leukemia & lymphoma, 2017-04

Cancer, 2010-08-15

J. Clin. Oncol., 2018 Jul 05

Journal of the American Academy of Dermatology, 2015-02

Int. J. Radiat. Oncol. Biol. Phys., 2017 Jun 09

Lancet (London, England), 2019-01-19

Blood, 2017-03-09

Cancer treatment reviews, 2017-02

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-03-10

J. Clin. Oncol., 2009 Oct 05

Ann. Oncol.,

Cancer Res., 2010 Feb 02

Dig Liver Dis, 2013 Jun 28

Am. J. Clin. Oncol.,

The New England journal of medicine, 2017-04-06

Haematologica, 2011 Nov 04

Radiother Oncol, 2011 Jun 12

Int. J. Radiat. Oncol. Biol. Phys., 2012 Mar 13

Blood, 2018 Sep 04

Clin. Cancer Res., 2011 Feb 16

J. Clin. Oncol., 2013 Oct 21

Bone marrow transplantation, 2018-07

Arch. Pathol. Lab. Med.,

Int. J. Radiat. Oncol. Biol. Phys.,

Blood, 2017-02-02

The Lancet. Haematology, 2016-05

The Lancet. Haematology, 2017-11

Blood, 2016 Mar 21

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-20

N. Engl. J. Med.,

Blood, 2018-03-15

Cancer, 2015-12-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-08-01

Neuro-oncology, 2009-04

Lancet Haematol, 2015 Jun 03

Mediterr J Hematol Infect Dis, 2017 Apr 15

Annals of oncology : official journal of the European Society for Medical Oncology, 2011-02

Haematologica, 2016 Jun 16

The New England journal of medicine, 2017-08-03

Lancet, 2012 Apr 05

Haematologica, 2018 Aug 03

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-07-10


Annals of oncology : official journal of the European Society for Medical Oncology, 2007-04

Leukemia, 2014-03

Cancer, 2015-04-01

Oncology (Williston Park, N.Y.), 2014-12

Cancer, 2014-12-01

Blood, 2019-04-04

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018-06

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-10

International journal of radiation oncology, biology, physics, 2018-07-15

Haematologica, 2017 Sep 21

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-01-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-07-10

British journal of haematology, 2015-12

Blood Adv,

The Lancet. Oncology, 2014-03

The New England journal of medicine, 2012-05-10

Leukemia, 2019-01

Blood, 2017 Aug 3

J Clin Oncol, 2020 Jul 13

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-09-01

J. Clin. Oncol., 2019 Sep 10

Acta Paediatr., 2020 Mar 23

American journal of hematology, 2018-08

Am. J. Hematol., 2019 Nov 19

International journal of radiation oncology, biology, physics, 2018-09-01

Cancer Treat Rep,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-02-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-11-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-07-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-03-20

J. Clin. Oncol.,


N. Engl. J. Med.,

QJM, 2013 Feb 27

Nature medicine, 2015-02

Clin Lymphoma Myeloma Leuk, 2017 Jun 21

The New England journal of medicine, 2007-01-25

Haematologica, 2020

Nature, 2019-03

Blood, 2018 May 02

Blood, 2016-07-28

Blood advances, 2016-12-27

Cancer, 2016-10

Blood, 2017-08-31

Biol. Blood Marrow Transplant., 2019 Aug 22

Leukemia & lymphoma, 2017-12

Int. J. Radiat. Oncol. Biol. Phys., 2012 Jul 24

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2016-04

Blood, 2018 Jul 12

Ann. Intern. Med., 2019 Oct 15

Blood Transfus, 2018 Oct 24

J Thromb Haemost, 2018 May 08

, 2016 Apr 26

AJR Am J Roentgenol,

J Hematol Oncol, 2018 Jan 16

Blood, 2017-07-06

The Lancet. Oncology, 2019-06

Blood, 2015-05-28

Blood Adv, 2020 Jan 28

Blood, 2015 Aug 24

Leukemia, 2016-04


Blood, 2016 Dec 27

Blood, 2008-05-15

The New England journal of medicine, 2019-02-21

J Thromb Haemost, 2019 Jul 28

N Engl J Med, 2018 Dec 04

Blood, 2018 Apr 5

N Engl J Med,

The New England journal of medicine, 2017-02-02

Blood, 2009 Nov 10

Chest, 1975-12

Clin Nephrol,

Eur J Intern Med, 2016 Dec 02

Ann Hematol, 2017 Nov 21

American journal of hematology, 2011-10

The American journal of medicine, 2017-12

Am J Hematol, 2019 Sep